Literature DB >> 3918169

Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors.

N F Ford, L J Browne, T Campbell, C Gemenden, R Goldstein, C Gude, J W Wasley.   

Abstract

The synthesis and structure-activity profile of a new class of potent and highly specific thromboxane A2 synthetase inhibitors is described. The most potent member of this series in vitro is determined to be imidazo[1,5-a]-pyridine-5-hexanoic acid (9).

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3918169     DOI： 10.1021/jm00380a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

2.  Synthesis, characterization, optical properties and theoretical studies of novel substituted imidazo[1,5-a]pyridinyl 1,3,4-oxadiazole derivatives.

Authors:  Yan-Qing Ge; Teng Wang; Gui Yun Duan; Li Hua Dong; Xiao Qun Cao; Jian Wu Wang
Journal:  J Fluoresc       Date:  2012-06-28       Impact factor: 2.217

3.  Palladium-Catalyzed Highly Regioselective C-3 Arylation of Imidazo[1,5-a]pyridine.

Authors:  Chunhui Huang; Alexandros Giokaris; Vladimir Gevorgyan
Journal:  Chem Lett       Date:  2011       Impact factor: 1.389

4.  Effects of cicletanine on the urinary excretion of prostanoids and kallikrein, and on renal function in man.

Authors:  K Tsunoda; K Abe; K Omata; T Hagino; N Minami; M Munakata; K Yoshida; H Sakuma; S Misawa; S Arima
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

5.  Multicomponent Reaction Based Synthesis of 1-Tetrazolylimidazo[1,5- a]pyridines.

Authors:  Santosh Kurhade; Elmar Diekstra; Fandi Sutanto; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Alexander Dömling
Journal:  Org Lett       Date:  2018-06-26       Impact factor: 6.005
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.